Travellers fully vaccinated with Covaxin can enter US from Nov 8

The last-minute addition comes less than one week before the US launches its new travel system, granting entry to travellers who have received a vaccine that has been approved by the FDA or WHO.

covaxin, bharat biotech, coronavirus vaccine, covid-19, vaccination
Bharat Biotech's Covaxin
ANI US
2 min read Last Updated : Nov 04 2021 | 8:48 AM IST

Travellers fully vaccinated against COVID-19 with Covaxin have been given the green light to enter the US from November 8.

Talking to ANI over updating the approved travel list for Covaxin, CDC press officer, Scott Pauley said, "CDC's travel guidance applies to FDA approved or authorized and WHO Emergency Use Listing vaccines and encompasses any new vaccines that may be added to either of those lists over time."

The last-minute addition comes less than one week before the US launches its new travel system, which grants entry to foreign travellers who have received a vaccine that has been approved for emergency use by the US Food and Drug Administration (FDA) or WHO.

The US Centers for Disease Control (CDC) on Wednesday acknowledged the World Health Organisation's (WHO) granting emergency use listing (EUL) to India's indigenous vaccine Covaxin, developed by Bharat Biotech.

The WHO said in a tweet that the Technical Advisory Group, convened by World Health Organisation (WHO), has determined that the Hyderabad-based Bharat Biotech's COVID-19 vaccine meets WHO standards for protection against COVID-19.

"WHO has granted emergency use listing (EUL) to COVAXIN®[?] (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #COVID19," WHO said in a tweet.

The new US travel rules will also accept travellers fully vaccinated with Pfizer-BioNTech, Johnson & Johnson, Moderna, Oxford-AstraZeneca, Covishield, Sinopharm and Sinovac.

Covaxin, developed by the Indian biotechnology company Bharat Biotech in partnership with the Indian Council of Medical Research, has a 78 per cent efficacy rate against COVID-19 and is "extremely suitable" for low- and middle-income countries because it is easy to store, according to WHO.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus Vaccinewholesale mandisWHOUS FDA

First Published: Nov 04 2021 | 8:48 AM IST

Next Story